SKŘIVANOVÁ, Kateřina, Marcela BENDOVÁ, Ladislav DUŠEK, Daniela ŽÁČKOVÁ, Zdeněk RÁČIL a Jiří MAYER. The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia. Journal of Blood Disorders & Transfusion. Los Angeles: OMICS Publishing Group, 2013, roč. 4, č. 6, s. 1000167-1000171. ISSN 2155-9864. Dostupné z: https://dx.doi.org/10.4172/2155-9864.1000167. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1161814, author = {Skřivanová, Kateřina and Bendová, Marcela and Dušek, Ladislav and Žáčková, Daniela and Ráčil, Zdeněk and Mayer, Jiří}, article_location = {Los Angeles}, article_number = {6}, doi = {http://dx.doi.org/10.4172/2155-9864.1000167}, keywords = {Quality of life; CML; Comorbidities; Imatinib; Cancer treatment; Oncology}, language = {eng}, issn = {2155-9864}, journal = {Journal of Blood Disorders & Transfusion}, note = {This study was supported by the Czech Leukemia Study Group for Life (CELL).}, title = {The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia}, url = {http://www.omicsonline.org/the-effect-of-imatinib-treatment-duration-on-the-quality-of-the-life-of-patients-with-chronic-myeloid-leukemia-2155-9864.1000167.php?aid=21148}, volume = {4}, year = {2013} }
TY - JOUR ID - 1161814 AU - Skřivanová, Kateřina - Bendová, Marcela - Dušek, Ladislav - Žáčková, Daniela - Ráčil, Zdeněk - Mayer, Jiří PY - 2013 TI - The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia JF - Journal of Blood Disorders & Transfusion VL - 4 IS - 6 SP - 1000167 EP - 1000167 PB - OMICS Publishing Group SN - 21559864 N1 - This study was supported by the Czech Leukemia Study Group for Life (CELL). KW - Quality of life KW - CML KW - Comorbidities KW - Imatinib KW - Cancer treatment KW - Oncology UR - http://www.omicsonline.org/the-effect-of-imatinib-treatment-duration-on-the-quality-of-the-life-of-patients-with-chronic-myeloid-leukemia-2155-9864.1000167.php?aid=21148 N2 - Purpose: The objective of this study was to evaluate the quality of life (QL) as well as the frequency and severity of depression in patients with chronic phase chronic myeloid leukemia (CP-CML) in relation to the duration of Imatinib treatment. Methods: A detailed analysis of 56 adult patients with CP CML divided into groups according to the length of Imatinib treatment was performed as follows: Group A (n=28)- patients treated for 15 months (median); and Group B (n=28)-patients treated for 50 months (median). All used questionnaires EORTC QLQ-C30 (version 2), SF 36 and BDI were localized and validated. Results: The results from the QL questionnaires found a trend in the improvement in the QL of patients treated with Imatinib for 50 months (median) compared to patients treated for 15 months (median) only. However, a statistically significant improvement in the QL of patients with longer Imatinib treatment was found only in patients without co-existing invalidity and/or rheumatic disease. Moreover, these two comorbidities increased the level of depressive symptoms in patients with CML during the early period of Imatinib therapy. Conclusion: We found a trend in the improvement in the QL of patients with CML in relation to the duration of Imatinib therapy. Statistically significant improvement in the QL of patients with longer Imatinib treatment was found in patients without co-existing invalidity and/or rheumatic disease only. ER -
SKŘIVANOVÁ, Kateřina, Marcela BENDOVÁ, Ladislav DUŠEK, Daniela ŽÁČKOVÁ, Zdeněk RÁČIL a Jiří MAYER. The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia. \textit{Journal of Blood Disorders \&{} Transfusion}. Los Angeles: OMICS Publishing Group, 2013, roč.~4, č.~6, s.~1000167-1000171. ISSN~2155-9864. Dostupné z: https://dx.doi.org/10.4172/2155-9864.1000167.
|